ML291（Cat No.:I011463）is a selective small molecule inhibitor that targets the protein CDK9 (cyclin-dependent kinase 9), a key regulator of transcriptional elongation. By inhibiting CDK9, ML291 effectively suppresses the phosphorylation of RNA polymerase II, leading to a reduction in the expression of pro-survival genes. This compound has shown promise in preclinical studies as a potential therapeutic for cancer and viral infections, as it can modulate the expression of genes involved in cell proliferation, apoptosis, and immune response. ML291 offers a novel approach for targeting transcriptional regulation in disease treatment.